En español



Step Two - Funding Options

Small Business Funding flowchart

Understand your funding options:

Grants vs. Contracts: What's the difference?


  • Business-initiated projects for general NIDA areas of interest
  • Application due dates = Apr 5, Aug 5, Dec 5
  • Phase II - Competing renewals (drug development only)


  • Response to NIDA-initiated specific needs
  • Contracts solicitations are released once per year in Aug
  • Application Due Date = Nov 9, 2010
  • Please check NIDA's areas of need – Mr. Brian O'Laughlin

NIH SBIR vs. STTRs: What's the difference?

SBIR = Small Business Innovation Research (SBIR) program
STTR = Small Business Technology Transfer (STTR) program

What is the "Fast-track" application initiative?

What is a "Fast-track" SBIR/STTR application?

www.drugabuse.gov image of an open pill bottle
  • NIH Fast-Track application is a single application consisting of Phase I and Phase II activities
  • Combined Phase I and Phase II "fast-track" applications enable applicants to tell a more complete, cogent story from feasibility to the commercialization plan (NOT-OD-06-004 - NIH site) in one peer review

Who should apply for "fast-track" SBIR/STTR applications?

  • Applicants with a scientifically meritorious idea w/ a high potential for commercialization
  • Need to have preliminary data to support the transition to Phase II

How do "fast-track" SBIR/STTR applications differ from standard SBIR/STTR applications?

  • The Phase I portion of a Fast-Track must specify clear, measurable goals (milestones) that should be achieved prior to initiating Phase II work.
  • The Fast-Track application must present a Commercialization Plan (maximum 15 pages) that addresses specific points as described in the SF424 (R&R) SBIR/STTR Application Guide.
  • Phase I application still must specify clear measurable goals / milestones that need to be achieved prior to Phase II
  • The Phase II application must include a Commercialization Plan (15-pg limit)
  • SBIR/STTR Application Guide (MS Word, 3.1MB and PDF, 2.9MB - NIH)

Phase II Competing Renewal Awards

  • Although Phase I/ II SBIR support is sufficient for early discovery/development efforts, it is not likely that these amounts will be adequate to support the kind of developmental work needed for compliance with the FDA's requirement for an investigational new drug (IND) and/or for clinical trials. Thus, in an effort to help bridge this potential funding gap, NIDA will accept competing renewals of Phase II SBIR/STTR grant applications from current Phase II awardees. Competitive renewals are designed to give businesses the opportunity to continue the process of developing new products that require approval of a Federal regulatory agency.
  • Prospective applicants are strongly encouraged to submit a letter of intent to the contact below that includes the following:
    1. Descriptive title of the proposed research
    2. Name, address, and telephone number of the Principal Investigator
    3. Names of other key personnel
    4. Participating institutions
  • Please direct your questions to Dr. Cathrine Sasek, 301-443-6071, concerning this program

    Search for Funding

    Featured Publication

    Mentoring, A Guide for Drug Abuse Researchers publication cover

    Mentoring: A Guide for Drug Abuse Researchers

    Discusses the importance of quality mentorship in drug abuse research and offers suggestions for creating a successful mentor and mentee relationship.